Genzyme buys gene therapy assets from Avigen
In keeping with its strategy to expand its own gene therapy portfolio, Genzyme has acquired a broad array of gene therapy assets from Avigen.
- Gene Therapy, Cell Therapy
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com